tetano
Editor, Senior Moderator
J Pediatr Gastroenterol Nutr
. 2023 Feb 1;76(2):e36-e44.
doi: 10.1097/MPG.0000000000003661. Epub 2022 Nov 23.
Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease
Jiri Bronsky[SUP] 1 [/SUP], Ivana Copova[SUP] 1 [/SUP], Marianna Durilova[SUP] 1 [/SUP], Denis Kazeka[SUP] 1 [/SUP], Michal Kubat[SUP] 1 [/SUP], Tereza Lerchova[SUP] 1 [/SUP], Eva Vlckova[SUP] 1 [/SUP], Katarina Mitrova[SUP] 1 2 [/SUP], Michal Rataj[SUP] 3 [/SUP], Adam Klocperk[SUP] 3 [/SUP], Anna Sediva[SUP] 3 [/SUP], Ondrej Hradsky[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: We prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of our pediatric patients over 12 years old with inflammatory bowel disease (IBD) to that of healthy controls and looked for predictors of its robustness.
Methods: Anti-receptor binding domain, anti-spike S2, and anti-nucleocapsid immunoglobin-G (IgG) and immunoglobin-A levels were measured in 139 pediatric patients with IBD [65 fully vaccinated (2 doses), median age 16.3, interquartile range (IQR) 15.2-17.8 years, median time from vaccination (IQR) 61.0 (42.0-80.0) days] and 1744 controls (46, 37-57 years) using microblot array.
Results: All IBD and control patients developed positive anti-receptor binding domain IgG antibodies at comparable titers. The proportion of observations with positive anti-spike S2 IgG was higher in patients with IBD than in controls [63% vs 21%, odds ratio 2.99 (1.51-5.90)], as was its titer [median (IQR) 485 (92-922) vs 79 [33-180] IU/mL]. Anti-receptor binding domain and anti-spike S2 IgG levels were associated with IBD status. We found an association between anti-spike S2 IgG levels and time since vaccination (β -4.85, 95% CI -7.14 to 2.71, P = 0.0001), history of SARS-CoV-2 polymerase chain reaction positivity (206.76, 95% CI 39.93-374.05, P = 0.0213), and anti-tumor necrosis factor treatment (-239.68, 95% CI -396.44-83.55, P = 0.0047). Forty-three percent of patients reported vaccination side effects (mostly mild). Forty-six percent of observations with positive anti-nucleocapsid IgG had a history of SARS-CoV-2 infection.
Conclusions: Patients with IBD produced higher levels of postvaccination anti-spike S2 antibodies than controls. Previous SARS-CoV-2 infection is associated with higher production of postvaccination antibodies and anti-tumor necrosis factor treatment with lower production.
. 2023 Feb 1;76(2):e36-e44.
doi: 10.1097/MPG.0000000000003661. Epub 2022 Nov 23.
Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease
Jiri Bronsky[SUP] 1 [/SUP], Ivana Copova[SUP] 1 [/SUP], Marianna Durilova[SUP] 1 [/SUP], Denis Kazeka[SUP] 1 [/SUP], Michal Kubat[SUP] 1 [/SUP], Tereza Lerchova[SUP] 1 [/SUP], Eva Vlckova[SUP] 1 [/SUP], Katarina Mitrova[SUP] 1 2 [/SUP], Michal Rataj[SUP] 3 [/SUP], Adam Klocperk[SUP] 3 [/SUP], Anna Sediva[SUP] 3 [/SUP], Ondrej Hradsky[SUP] 1 [/SUP]
Affiliations
- PMID: 36705698
- DOI: 10.1097/MPG.0000000000003661
Abstract
Objectives: We prospectively compared the postvaccination immunity to messenger ribonucleic acid BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine of our pediatric patients over 12 years old with inflammatory bowel disease (IBD) to that of healthy controls and looked for predictors of its robustness.
Methods: Anti-receptor binding domain, anti-spike S2, and anti-nucleocapsid immunoglobin-G (IgG) and immunoglobin-A levels were measured in 139 pediatric patients with IBD [65 fully vaccinated (2 doses), median age 16.3, interquartile range (IQR) 15.2-17.8 years, median time from vaccination (IQR) 61.0 (42.0-80.0) days] and 1744 controls (46, 37-57 years) using microblot array.
Results: All IBD and control patients developed positive anti-receptor binding domain IgG antibodies at comparable titers. The proportion of observations with positive anti-spike S2 IgG was higher in patients with IBD than in controls [63% vs 21%, odds ratio 2.99 (1.51-5.90)], as was its titer [median (IQR) 485 (92-922) vs 79 [33-180] IU/mL]. Anti-receptor binding domain and anti-spike S2 IgG levels were associated with IBD status. We found an association between anti-spike S2 IgG levels and time since vaccination (β -4.85, 95% CI -7.14 to 2.71, P = 0.0001), history of SARS-CoV-2 polymerase chain reaction positivity (206.76, 95% CI 39.93-374.05, P = 0.0213), and anti-tumor necrosis factor treatment (-239.68, 95% CI -396.44-83.55, P = 0.0047). Forty-three percent of patients reported vaccination side effects (mostly mild). Forty-six percent of observations with positive anti-nucleocapsid IgG had a history of SARS-CoV-2 infection.
Conclusions: Patients with IBD produced higher levels of postvaccination anti-spike S2 antibodies than controls. Previous SARS-CoV-2 infection is associated with higher production of postvaccination antibodies and anti-tumor necrosis factor treatment with lower production.